Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Actinogen Medical ( (AU:ACW) ) has issued an update.
Actinogen Medical announced the date for its Annual General Meeting, set for November 19, 2025, where the re-election and appointment of directors will be discussed. The company is advancing its clinical trials for Xanamem, a promising therapy for Alzheimer’s Disease and Depression, with significant progress in its XanaMIA and XanaCIDD trials, which could impact the treatment landscape for these conditions.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. The company’s lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease and Depression, with potential future applications in Fragile X Syndrome and other conditions.
YTD Price Performance: 28.00%
Average Trading Volume: 2,942,808
Technical Sentiment Signal: Hold
Current Market Cap: A$101.6M
For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.